VIRAMUNE XR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Mar 2011
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIRAMUNE XR is an extended-release oral tablet approved in 2011 for viral infection treatment, representing a small-molecule therapeutic in the antiretroviral class. The exact indication and mechanism of action are not specified in available data, but the XR formulation enables once-daily dosing for improved patient adherence. This product is part of Boehringer Ingelheim's established antiviral portfolio.
LOE Approaching2.9 years to LOE
With LOE approaching in 2.9 years and competitive pressure at 15 competitors, the brand team is likely in defensive maintenance mode with reduced headcount and focus on portfolio transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on VIRAMUNE XR at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.